Methionine synthase reductaseMTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients

The association of variants of the gene encoding methionine synthase reductase (MTRR) with hyperhomocysteinemia, folate and Vitamin B12 status in kidney graft recipients is unknown. We examined two mutations in MTRR in a cross-sectional study of 733 kidney graft recipients. The allele frequency of MTRR 66G was 0.55. 369 patients (50.3%) were heterozygous and 219 patients (29.9%) were homozygous for the mutation. None of the patients showed the 997C>G mutation. The allelic variants of MTRR 66A>G showed no significant association with total homocysteine (tHcy) levels, both in univariate analyses, and in a multivariate model controlling for age, gender, body mass index, renal function, time since transplantation, underlying kidney disease, as well as the MTHFR 677C>T/1298A>C genotypes. Similarly, no significant associations between the MTRR 66A>G genotypes and plasma folate or Vitamin B12 levels were found. In conclusion, MTRR 66A>G has no major effect on tHcy, folate, or Vitamin B12 plasma concentrations in kidney graft recipients.